A groundbreaking smart menstrual pad technology developed by healthtech startup Truelli is revolutionizing women’s healthcare by transforming menstrual blood into a powerful diagnostic tool. Announced on September 19, 2025, this innovative device represents the world’s first menstrual pad with built-in screening capabilities that can detect health abnormalities instantly.
The smart pad analyzes menstrual blood, an information-rich biomarker that has been historically overlooked by the medical community. Through advanced technology, the device assesses four critical health indicators: nutrient levels, hormonal fluctuations, metabolic function, and sexual health. Results are delivered through a companion mobile application that provides actionable health insights.
Revolutionary Health Screening Technology
Truelli’s smart menstrual pad operates through a simple three-step process that makes health monitoring accessible to women everywhere. Users wear the pad during their menstrual cycle, scan a barcode on the device using the Truelli app, and receive instant health results on their smartphone. This non-invasive approach eliminates the need for traditional blood draws or laboratory visits.
The technology can detect various health conditions including anemia, fatigue indicators, fertility markers, perimenopause signs, sexually transmitted infections, cancer markers, diabetes indicators, and cardiovascular health metrics. According to CEO Sabine Zureikat, “We believe every woman should have access to affordable health – it should never be a luxury.”
Addressing Healthcare Disparities
This innovation comes at a crucial time when women’s health research is gaining unprecedented attention and funding. The development aligns with recent major investments in women’s health, including the Gates Foundation’s $2.5 billion commitment to women-centered research and development. The smart pad technology addresses the persistent underrepresentation of women’s biology in healthcare research and product development.
Dr. Saba Alzabin, Truelli’s Co-Founder and Chief Scientific Officer, emphasizes the broader impact: “While innovation in women’s health is progressing, its impact is constrained by the lack of physiologically-relevant and robust research and development. At Truelli, we’re transforming overlooked biological signals within the female cycle into tools that can support women’s healthspan.”
The device has demonstrated medical efficiency through extensive clinical trials and maintains compliance with healthcare standards including UKAS accreditation and HIPAA requirements. Truelli prioritizes user safety by remaining free from chemicals and harsh ingredients, making it suitable for regular use.
Truelli has secured backing from notable investors including KBW Ventures, Meshari Al Jabr, Vital Ventures by Revival Lab, and 500 Global. This financial support underscores growing confidence in women’s health technology solutions and their potential for global impact, particularly in regions where systemic and cultural barriers limit healthcare access for women and girls.